TRCT
ZBIO

Tower Research Capital (TRC)’s Zenas BioPharma ZBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.6K Sell
1,286
-5,949
-82% -$118K ﹤0.01% 3100
2026
Q1 		$141K Buy
7,235
+6,440
+810% +$145K ﹤0.01% 1905
2025
Q4 		$28.9K Sell
795
-593
-43% -$19.5K ﹤0.01% 2828
2025
Q3 		$30.8K Sell
1,388
-1,158
-45% -$18.9K ﹤0.01% 2912
2025
Q2 		$24.7K Buy
2,546
+1,135
+80% +$11.1K ﹤0.01% 3555
2025
Q1 		$11.1K Buy
1,411
+294
+26% +$2.3K ﹤0.01% 3567
2024
Q4 		$9.15K Buy
+1,117
New +$17.4K ﹤0.01% 3934

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Tower Research Capital (TRC)'s ZBIO Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Zenas BioPharma (ZBIO) stake by 82% in Q2 2026, selling an estimated $118K and leaving 1,286 shares worth $32.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3100.

Tower Research Capital (TRC) first reported a position in ZBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $141K in Q1 2026. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Tower Research Capital (TRC) held 1,286 shares of Zenas BioPharma worth $32.6K as of Q2 2026.
  • Tower Research Capital (TRC) sold 5,949 Zenas BioPharma shares in Q2 2026, an estimated $118K.
  • Zenas BioPharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3100 holding.
  • Tower Research Capital (TRC) first reported a position in Zenas BioPharma in Q4 2024 and has held it in 7 quarters since.
  • Tower Research Capital (TRC)'s Zenas BioPharma position peaked at $141K in Q1 2026.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.